Literature DB >> 10426737

Predicted impact of intravenous thrombolysis on prognosis of general population of stroke patients: simulation model.

H S Jørgensen1, H Nakayama, L P Kammersgaard, H O Raaschou, T S Olsen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10426737      PMCID： PMC28179          DOI： 10.1136/bmj.319.7205.288

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  4 in total

1.  Tissue plasminogen activator for acute ischemic stroke.

Authors: 
Journal:  N Engl J Med       Date:  1995-12-14       Impact factor: 91.245

2.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators.

Authors:  W Hacke; M Kaste; C Fieschi; R von Kummer; A Davalos; D Meier; V Larrue; E Bluhmki; S Davis; G Donnan; D Schneider; E Diez-Tejedor; P Trouillas
Journal:  Lancet       Date:  1998-10-17       Impact factor: 79.321

3.  Effect of blood pressure and diabetes on stroke in progression.

Authors:  H S Jørgensen; H Nakayama; H O Raaschou; T S Olsen
Journal:  Lancet       Date:  1994-07-16       Impact factor: 79.321

4.  Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)

Authors:  W Hacke; M Kaste; C Fieschi; D Toni; E Lesaffre; R von Kummer; G Boysen; E Bluhmki; G Höxter; M H Mahagne
Journal:  JAMA       Date:  1995-10-04       Impact factor: 56.272
  4 in total
  9 in total

1.  Predicted impact of intravenous thrombolysis. Patients who died or recovered fully should have been included in analysis.

Authors:  J Berwaerts; A M Johnston; M J Macleod
Journal:  BMJ       Date:  2000-04-08

2.  Disease impact number and population impact number: population perspectives to measures of risk and benefit.

Authors:  R F Heller; A J Dobson
Journal:  BMJ       Date:  2000-10-14

Review 3.  Alteplase for stroke: money and optimistic claims buttress the "brain attack" campaign.

Authors:  Jeanne Lenzer
Journal:  BMJ       Date:  2002-03-23

4.  Why were the benefits of tPA exaggerated?

Authors:  Griffin Trotter
Journal:  West J Med       Date:  2002-05

5.  Should physicians give tPA to patients with acute ischemic stroke? Against: and just what is the emperor of stroke wearing?

Authors:  J R Hoffman
Journal:  West J Med       Date:  2000-09

6.  Lack of experience of intravenous thrombolysis for acute ischaemic stroke does not influence the proportion of patients treated.

Authors:  Adam Kobayashi; Marta Skowronska; Tomasz Litwin; Anna Czlonkowska
Journal:  Emerg Med J       Date:  2007-02       Impact factor: 2.740

Review 7.  New insights on thrombolytic treatment of acute ischemic stroke.

Authors:  J F Meschia; T G Brott
Journal:  Curr Neurol Neurosci Rep       Date:  2001-01       Impact factor: 5.081

8.  Factors that can affect the external validity of randomised controlled trials.

Authors:  Peter M Rothwell
Journal:  PLoS Clin Trials       Date:  2006-05

Review 9.  Future directions for intra-arterial therapy for acute ischaemic stroke: is there life after three negative randomized controlled studies?

Authors:  Julian Maingard; Bernard Yan
Journal:  Interv Neurol       Date:  2014-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.